Novo Nordisk cuts Wegovy prices in India to make obesity treatment more affordable
Mumbai – Danish drugmaker Novo Nordisk has slashed prices for all strengths of its weight-loss drug Wegovy, making the once-weekly injectable treatment more affordable for Indians battling chronic obesity. The company aims to expand access to obesity care and promote patient-focused healthcare.
Under the new rates, the starting dose of Wegovy (0.25 mg) now costs ₹2,712 per week, a sharp drop that reflects Novo Nordisk’s goal of reaching more patients. The highest dose of 2.4 mg now costs ₹16,400 per month, down from ₹24,389. The lowest dose pack costs ₹10,850, compared to ₹16,260 earlier.
Novo Nordisk launched Wegovy in India in June 2025, using its trademark FlexTouch pens that allow convenient, prefilled insulin and GLP-1 agonist dosing. The company said the price cut aligns with its mission to support sustainable and effective weight-loss treatments for Indians.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the decision came after listening to patients and doctors across the country. “We put patients before profits. This move shows our dedication to making obesity management safer, effective, and accessible,” he stated.
He stressed that obesity is rising fast in India, fueling conditions like diabetes, hypertension, and heart disease. He added that affordable access can help people take charge of their health early, before complications develop.
Wegovy, the only approved prescription-based obesity drug in India, reduces body weight and cardiovascular risk when used with healthy diet and exercise. It mimics a natural hormone that suppresses appetite and helps users eat less.
Clinical trials worldwide show promising results. Nearly one in three users lost up to 20% of body weight when using Wegovy alongside lifestyle changes. These results have boosted the drug’s demand among people struggling to lose weight despite regular exercise and diet control.
Experts note that while fitness routines remain vital, medical options like GLP-1 receptor agonists can support those facing chronic obesity resistant to conventional efforts. With the 37% price cut, India’s weight-loss market may now see stronger participation and growing patient trust in evidence-based treatments.
According to the National Family Health Survey (NFHS-5), nearly one in four Indian adults is overweight or obese, with rates climbing fastest in cities. Yet, limited access and high costs have kept advanced treatments like Wegovy out of reach for many.
Novo Nordisk’s latest move could mark a turning point. As awareness and affordability grow, India’s healthcare sector may finally bridge the gap between lifestyle advice and scientific obesity management — helping millions lead healthier, longer lives.
